|
Hemato-oncology / Original Article
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
Sehhoon Park, Ji-Yeon Kim, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2017;32(3):514-522. Published online April 14, 2017
Background/Aims: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the predictive value of KRAS mutations and its mutation types to pemetrexed and gemcitabine based t..
|
|
|
Hemato-oncology / Original Article
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small
cell lung cancer with activating epidermal growth factor receptor mutations
Sehhoon Park, Seongyeol Park, Se-Hoon Lee, Beomseok Suh, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Young Whan Kim, Dae Seog Heo
Korean J Intern Med. 2016;31(6):1140-1149. Published online March 28, 2016
Background/Aims: Pretreatment nutritional status is an important prognostic factor in patients treated with conventional cytotoxic chemotherapy. In the era of target therapies, its value is overlooked and has not been investigated. The aim of our study is to evaluate the value of nutritional status ..
|
|
|
Hemato-oncology / Original Article
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation
Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Doo Hee Han, Tae-Bin Won, Se-Hoon Lee, J. Hun Hah, Tack-Kyun Kwon, Dong-Wan Kim, Dong-Young Kim, Chae-Seo Rhee, Hong-Gyun Wu, Myung-Whun Sung, Dae Seog Heo
Korean J Intern Med. 2016;31(3):570-578. Published online March 15, 2016
Background/Aims: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We ev..
|
|
|
Hemato-oncology / Original Article
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
Kyoung Min Cho, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Dae Seog Heo
Korean J Intern Med. 2015;30(6):891-898. Published online October 30, 2015
Background/Aims: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure.
Methods: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National Uni..
|
|
|
Nephrology / Original Article
Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea
Seon Ha Baek, Hyunsuk Kim, Jeonghwan Lee, Dong Ki Kim, Kook-Hwan Oh, Yon Su Kim, Jin Suk Han, Tae Min Kim, Se-Hoon Lee, Kwon-Wook Joo
Korean J Intern Med. 2014;29(1):40-48. Published online January 2, 2014
Background/Aims: Sunitinib is an oral multitargeted tyrosine kinase inhibitor
used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse
effects (RAEs) of sunitinib have not been investigated. The aim of this study
was to determine the incidence and risk factors of RAEs (..
|
|
|
